Abbott Laboratories has settled a patent litigation case against Ranbaxy Laboratories, allowing the Indian pharmaceutical firm to launch a generic version of the US drugmaker’s cholesterol lowering medicine Tricor. It could bring several million dollars in revenues for Ranbaxy. Abbott which sells feno fibrate under the brands Tricor and Triplix generates about $1 billion in annual sales from the American market alone.
It could not be ascertained when Ranbaxy would be able to launch its drug in the US. But Abbott had earlier settled with another generic drug maker Teva for 145 mg dosage of same medicine that permits the Israeli firm to launch its low-priced version as early as March 2011.
In June last year, Japan’s Daiichi Sankyo-owned Ranbaxy had informed Abbott that it plans to launch its generic version of Tricor in 45 mg and 145 mg dosages. The innovator sued Ranbaxy and as per American laws received a 30-month automatic stay on the case.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: